A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis

Inclusion Criteria: * Male or female outpatients aged 18 to 75 years with chronic plaque psoriasis * Plaque psoriasis covering ≥ 10% BSA * Disease duration ≥ 6 months * PASI ≥ 12.0 at screening Exclusion Criteria: * Guttate, erythrodermic or pustular psoriasis as sole or predominant form of the disease * Clinically significant psoriasis flare during screening or at time of enrollment * Systemic therapy for psoriasis or systemic immunosuppressive therapy for other indications within 28 days prior to enrollment * Topical treatment for psoriasis within 14 days prior to enrollment * Use of CYP3A4 moderate and strong inhibitors within 4 weeks prior to randomization * Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection